BCG-COVID-RCT: BCG vaccine to reduce absenteeism due to infectious diseases of health workers during the COVID-19 pandemic. A multi-centre randomised controlled trial

  • Funded by European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Total publications:5 publications

Grant number: RIA2020EF-3049

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $583,727.12
  • Funder

    European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Principle Investigator

    Pending
  • Research Location

    Denmark, Europe
  • Lead Research Institution

    University of Southern Denmark
  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    Economic impacts

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The BCG-COVID-RCT project (RIA2020EF-3049) aims to study the BCG non-specific protection of healthcare workers against COVID-19.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Effects of Neonatal BCG-Japan Versus BCG-Russia Vaccination on Overall Mortality and Morbidity: Randomized Controlled Trial From Guinea-Bissau (BCGSTRAIN II).

Mortality Risk Among Frail Neonates and Maternal BCG Vaccine Scar Status: Observational Study From Guinea-Bissau.

The association between parental and neonatal BCG vaccination and neonatal T helper 17 cell expansion.

Immediate Bacille Calmette-Guérin Vaccination to Neonates Requiring Perinatal Treatment at the Maternity Ward in Guinea-Bissau: A Randomized Controlled Trial.

Maternal BCG primes for enhanced health benefits in the newborn.